Skip to main content
. 2022 Jul 26;34(2):133–147. doi: 10.4103/joco.joco_308_21

Figure 9.

Figure 9

Estimated weighted mean difference of improvement in best-corrected visual acuity with aflibercept in comparison with ranibizumab at 12 months stratified by randomized controlled trial (RCT) (pictured top) vs. non-RCT (pictured bottom) as measured using Early Treatment Diabetic Retinopathy Study (ETDRS) letters. 12-month RCTs: Weighted mean difference between aflibercept and ranibizumab: 2.19 ETDRS letters, P = 0.027. 12-month non-RCTs: Weighted mean difference between aflibercept and ranibizumab: 1.53 ETDRS letters, P = 0.058. Note: Only comparator groups with more than one study in both RCT and non-RCT groups were represented in stratified analyses; thus, no comparator groups were represented in stratified analyses at 24 months. Afl: aflibercept, CI: Confidence interval.